Published in Ann Surg on January 01, 2008
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med (2012) 1.68
Endothelial nitric oxide synthase deficiency causes collateral vessel rarefaction and impairs activation of a cell cycle gene network during arteriogenesis. Circ Res (2010) 1.48
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med (2009) 1.47
The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47. Matrix Biol (2012) 1.34
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem (2008) 1.34
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem (2010) 1.27
Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm (2011) 1.24
Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci (2008) 1.23
CD47 regulates bone mass and tumor metastasis to bone. Cancer Res (2009) 1.14
Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann Surg (2008) 1.13
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery (2008) 1.12
CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol (2012) 1.06
CD47: a new target in cardiovascular therapy. Arterioscler Thromb Vasc Biol (2008) 1.05
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective. Plast Reconstr Surg (2009) 1.05
Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep (2013) 1.05
Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide (2009) 0.99
The interaction of Thrombospondins with extracellular matrix proteins. J Cell Commun Signal (2009) 0.97
Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol (2011) 0.94
Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J Immunol (2010) 0.92
CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit Rev Biochem Mol Biol (2015) 0.90
Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease. Matrix Biol (2014) 0.90
Molecular regulation of tumor angiogenesis and perfusion via redox signaling. Chem Rev (2009) 0.89
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets (2012) 0.89
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling. Curr Drug Targets (2008) 0.88
Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation. J Genet Syndr Gene Ther (2011) 0.86
Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals (Basel) (2011) 0.84
Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice. Matrix Biol (2014) 0.83
(-)-Epicatechin is associated with increased angiogenic and mitochondrial signalling in the hindlimb of rats selectively bred for innate low running capacity. Clin Sci (Lond) (2013) 0.79
Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg (2013) 0.79
Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget (2015) 0.79
A novel dermal matrix generated from burned skin as a promising substitute for deep‑degree burns therapy. Mol Med Rep (2016) 0.78
Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow. Front Physiol (2014) 0.78
CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model. Transplantation (2014) 0.77
Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling. Int J Biochem Cell Biol (2016) 0.76
PADPIN: protein-protein interaction networks of angiogenesis, arteriogenesis, and inflammation in peripheral arterial disease. Physiol Genomics (2015) 0.76
Pre-vascularization Enhances Therapeutic Effects of Human Mesenchymal Stem Cell Sheets in Full Thickness Skin Wound Repair. Theranostics (2017) 0.75
Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation. Front Physiol (2017) 0.75
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol (2002) 3.08
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol (1990) 2.69
The functions of thrombospondin-1 and-2. Curr Opin Cell Biol (2000) 2.56
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem (2006) 2.23
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res (1994) 2.20
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A (2005) 2.17
Increasing survival of ischemic tissue by targeting CD47. Circ Res (2007) 2.16
Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol (1993) 2.10
The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int J Biochem Cell Biol (2004) 2.01
State of the art in burn treatment. World J Surg (2005) 1.88
Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol (2004) 1.77
Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta (2005) 1.76
Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res (2006) 1.63
Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and in situ hybridization. J Histochem Cytochem (1993) 1.56
Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood (2006) 1.56
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res (2006) 1.43
Diabetes and burns: retrospective cohort study. J Burn Care Rehabil (2002) 1.34
New technologies for burn wound closure and healing--review of the literature. Burns (2005) 1.28
Thrombospondin-1. Int J Biochem Cell Biol (1997) 1.21
Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation (2003) 1.20
Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice. Am J Pathol (2001) 1.15
Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol (2005) 1.14
Early tangential excision and skin grafting of moderate burns is superior to honey dressing: a prospective randomised trial. Burns (1999) 1.09
Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can J Appl Physiol (2005) 1.09
The use of cultured epithelial autograft in the treatment of major burn injuries: a critical review of the literature. Burns (2006) 1.03
Principles and practices for treatment of cutaneous wounds with cultured skin substitutes. Am J Surg (2002) 1.00
Experience of 14 years of emergency reconstruction of electrical injuries. Burns (2003) 1.00
Analysis of skin-graft loss due to infection: infection-related graft loss. Ann Plast Surg (2005) 0.98
The burn patient: II. Later care and complications of thermal injury. Curr Probl Surg (1979) 0.96
Role of nitric oxide in surgical flap survival. J Am Coll Surg (2005) 0.94
Vascular nitric oxide: effects of physical activity, importance for health. Essays Biochem (2006) 0.90
Nitric oxide modulation of early angiogenesis. Microsurgery (2004) 0.89
Effects of early enteral arginine supplementation on resuscitation of severe burn patients. Burns (2006) 0.88
Sulfatide protects rat skin flaps against ischemia-reperfusion injury. J Surg Res (1998) 0.87
Failure characteristics of multiple-component fibrin-based adhesives. J Biomed Mater Res (2002) 0.86
Permanent restoration of human skin treated with cultured epithelium grafting--wound healing by stem cell based tissue engineering--. Hum Cell (2002) 0.84
Skin grafting and wound healing-the "dermato-plastic team approach". Clin Dermatol (2005) 0.84
Complications of thermal injury. Clin Plast Surg (1974) 0.84
Recipient bed vascularity and the survival of ischaemic flaps. Br J Plast Surg (1997) 0.83
Primary excision and immediate wound closure. Intensive Care Med (1981) 0.81
The use of homografts in burn therapy. Surg Clin North Am (1970) 0.81
Effects of nitric oxide synthase inhibition on blood flow and survival in experimental skin flaps. J Plast Reconstr Aesthet Surg (2006) 0.79
The protective effect of L-arginine on ischemia-reperfusion injury in rat skin flaps. Plast Reconstr Surg (1997) 0.78
Development and evaluation of an in vivo mouse model for studying myocutaneous flap microcirculation and viability before and after suturing or stapling. Int J Microcirc Clin Exp (1994) 0.78
Use of urokinase during secondary ischemia in experimental skin flaps. Ann Plast Surg (1994) 0.78
The effect of single administration of vascular endothelial growth factor or L-arginine on necrosis and vasculature of the epigastric flap in the rat model. Br J Plast Surg (2004) 0.78
Pathology of cutaneous burns. Surg Clin North Am (1970) 0.78
Acute management of thermal injury. Ann Plast Surg (1981) 0.77
Intravenous nitroglycerin as a means of improving ischemic tissue hemodynamics and survival. Ann Plast Surg (1986) 0.77
A new method for securing skin grafts in pediatric patients. Plast Reconstr Surg (2003) 0.77
Thermal burn fatalities in the workplace, United States, 1992 to 1999. J Burn Care Rehabil (2002) 0.77
New techniques in burn wound management. Surg Clin North Am (1993) 0.76
CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol (2009) 5.87
A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A (2008) 5.48
Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol (2012) 4.72
The emerging biology of the nitrite anion. Nat Chem Biol (2005) 2.88
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol (2004) 2.61
Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch (2005) 2.45
CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem (2006) 2.23
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis. Nature (2008) 2.18
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A (2005) 2.17
Increasing survival of ischemic tissue by targeting CD47. Circ Res (2007) 2.16
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Regulation of the yeast Rlm1 transcription factor by the Mpk1 cell wall integrity MAP kinase. Mol Microbiol (2002) 1.92
Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res (2010) 1.91
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci U S A (2003) 1.78
Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci U S A (2003) 1.76
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood (2007) 1.73
A protein from the salivary glands of the pea aphid, Acyrthosiphon pisum, is essential in feeding on a host plant. Proc Natl Acad Sci U S A (2008) 1.69
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res (2006) 1.56
Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood (2006) 1.56
Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A (2005) 1.55
Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood (2005) 1.55
Subcellular localization of trifluoroacetylated liver proteins in association with hepatitis following isoflurane. Anesthesiology (2002) 1.54
Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2- reaction. Proc Natl Acad Sci U S A (2002) 1.53
Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr Blood Cancer (2011) 1.53
Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest (2010) 1.52
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res (2003) 1.52
Small molecule signaling agents: the integrated chemistry and biochemistry of nitrogen oxides, oxides of carbon, dioxygen, hydrogen sulfide, and their derived species. Chem Res Toxicol (2012) 1.51
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med (2009) 1.47
The reduction potential of nitric oxide (NO) and its importance to NO biochemistry. Proc Natl Acad Sci U S A (2002) 1.45
Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency. Hum Mol Genet (2003) 1.45
Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int (2004) 1.44
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res (2006) 1.43
Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer (2005) 1.42
The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther (2006) 1.41
C4d deposits on the surface of RBCs in trauma patients and interferes with their function. Crit Care Med (2014) 1.41
Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem (2007) 1.41
Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol (2004) 1.38
Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity? J Clin Endocrinol Metab (2004) 1.38
Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer (2007) 1.38
Arginine-induced germ tube formation in Candida albicans is essential for escape from murine macrophage line RAW 264.7. Infect Immun (2009) 1.38
The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem (2004) 1.37
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem (2008) 1.34
CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res (2004) 1.33
Focusing of nitric oxide mediated nitrosation and oxidative nitrosylation as a consequence of reaction with superoxide. Proc Natl Acad Sci U S A (2002) 1.33
The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal (2006) 1.32
Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo. Circ Res (2003) 1.32
Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res (2008) 1.30
Interactions of thrombospondins with alpha4beta1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol (2002) 1.29
Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res (2007) 1.28
Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med (2003) 1.28
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem (2010) 1.27
CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy (2012) 1.27
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol (2008) 1.26
Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A (2007) 1.26
Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis (2009) 1.26
Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in Vivo. J Med Chem (2005) 1.26
Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease. Mol Med (2012) 1.26
Nitroxyl (HNO): chemistry, biochemistry, and pharmacology. Annu Rev Pharmacol Toxicol (2005) 1.25
Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol (2007) 1.25